LobbyingRevangenix lobbying by quarter
Revangenix's latest lobbying report covers Q1 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $50K. Its first report covers Q1 2024; the issues it reports most are Health Issues.
Revangenix
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $50K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q1 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2024 | $30K | 1 |
| Q2 2024 | $50K | 1 |
| Q3 2024 | $50K | 1 |
| Q4 2024 | $50K | 1 |
| Q1 2025 | $50K | 1 |
| Q2 2025 | $50K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$380K · 8 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES8 reports
- SENATE8 reports
Firms it paid
| Firm | ||
|---|---|---|
| Forbes-Tate | $380K | 9 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 04/08for Q1 | Forbes-Tate | Under $5,000 |
| 01/18for Q4 2025 | Forbes-Tate | $50K |
| 25/10/19for Q3 2025 | Forbes-Tate | $50K |
| 25/07/17for Q2 2025 | Forbes-Tate | $50K |
| 25/04/15for Q1 2025 | Forbes-Tate | $50K |
| 25/01/19for Q4 2024 | Forbes-Tate | $50K |
| 24/10/17for Q3 2024 | Forbes-Tate | $50K |
| 24/07/13for Q2 2024 | Forbes-Tate | $50K |
| 24/04/14for Q1 2024 | Forbes-Tate | $30K |
| 24/03/20for Q1 2024 | Forbes-Tate | Under $5,000 |